PDF(Pubmed)
Abstract：
Background: With this study, we investigate the short-term clinical outcomes of patients affected by diabetic macular edema (DME) after switching to intravitreal Faricimab (IVF) in a real-world setting. Methods: We conducted a retrospective chart review on all patients treated for DME with IVF who showed insufficient responses to prior anti-VEGF therapy. Data collected included baseline patient demographics, medical history, best-corrected visual acuity (BCVA), central retinal thickness (CRT) and central retinal volume (CRV). We analyzed functional and structural measures before and after IVF, compared baseline demographics and treatment factors between Faricimab-responders and reduced-responders and assessed influencing factors of the follow-up BCVA and CRT. Results: This study included 25 eyes from 16 patients. After switching to IVF, the mean BCVA showed no significant improvement, changing from 59.4 ± 13.4 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters at baseline to 61.4 ± 12.8 ETDRS letters at follow-up (p = 0.26). CRT significantly reduced from 414.4 ± 126.3 µm to 353.3 ± 131.1 µm (p < 0.011), and the 3 mm CRV significantly decreased from 2.8 ± 0.5 mm3 to 2.6 ± 0.6 mm3 (p < 0.012). Seven patients met the responder criteria, exhibiting an improvement of at least 5 ETDRS letters and a simultaneous CRT reduction of at least 30 µm. Further analysis showed that higher BCVA at baseline (p < 0.001) was associated with better BCVA following IVF, while higher baseline CRT (p < 0.003), a higher number of prior anti-VEGF agents (p < 0.034) and prior corticosteroid injections (p < 0.019) were associated with greater CRT at follow-up. Conclusions: Following the initial IVF injection series, we observed a clear improvement of anatomical measures. No functional improvement was observed, although visual acuity remained stable. Higher baseline BCVA was associated with better post-IVF BCVA, while higher baseline CRT, a greater number of prior anti-VEGF agents and prior corticosteroid injections were linked to higher CRT post-IVF.
摘要：
背景:通过本研究,我们调查了糖尿病性黄斑水肿(DME)患者在现实环境中转用玻璃体腔注射法利玛单抗(IVF)后的短期临床结局.方法：我们对所有接受IVF治疗的DME患者进行了回顾性分析，这些患者对先前的抗VEGF治疗反应不足。收集的数据包括基线患者人口统计学，病史,最佳矫正视力（BCVA），中央视网膜厚度（CRT）和中央视网膜体积（CRV）。我们分析了试管婴儿前后的功能和结构措施，比较Faricimab应答者和减少应答者之间的基线人口统计学和治疗因素，并评估随访BCVA和CRT的影响因素。结果：本研究包括16例患者的25只眼。切换到IVF后，平均BCVA没有显着改善，从基线时的59.4±13.4糖尿病视网膜病变早期治疗研究（ETDRS）字母变为随访时的61.4±12.8个ETDRS字母（p=0.26）。CRT从414.4±126.3µm显著降低至353.3±131.1µm（p<0.011），3mmCRV从2.8±0.5mm3下降到2.6±0.6mm3（p<0.012）。七名患者符合响应者标准，表现出至少5个ETDRS字母的改善和至少30µm的同时CRT减少。进一步的分析表明，基线时更高的BCVA（p<0.001）与IVF后更好的BCVA相关，而较高的基线CRT（p<0.003），较高的既往抗VEGF药物(p<0.034)和既往皮质类固醇注射(p<0.019)与随访时更高的CRT相关.结论：在最初的IVF注射系列之后，我们观察到解剖学措施的明显改善。没有观察到功能改善，虽然视力保持稳定。较高的基线BCVA与更好的IVF后BCVA相关，而较高的基线CRT，较多的既往抗VEGF药物和既往皮质类固醇注射与IVF后较高的CRT相关.
